Orum Therapeutics, Inc. Logo

Orum Therapeutics, Inc.

Developing degrader-antibody conjugates for cell-selective protein degradation to treat cancer.

475830 | KO

Overview

Corporate Details

ISIN(s):
KR7475830006
LEI:
Country:
South Korea
Address:
대전광역시 유성구 문지로 281-25, 대전광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Orum Therapeutics, Inc. is a clinical-stage biotechnology company pioneering a novel class of therapeutics using its proprietary TPD²® platform for cell-selective degradation. This technology combines the power of targeted protein degraders with the precision of antibodies to create degrader-antibody conjugates (DACs). The company's approach is designed to improve upon the efficacy, safety, and half-life of conventional protein degraders. Orum is focused on building a portfolio of highly differentiated products to treat diseases with high unmet medical needs, including cancer, by expanding the landscape of druggable targets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-16 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 352.9 KB
2025-08-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 348.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-08 00:00
Major Shareholding Notification
[기재정정]주식등의대량보유상황보고서(일반)
Korean 382.4 KB
2025-08-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 339.8 KB
2025-08-01 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 10.7 KB
2025-08-01 00:00
Remuneration Information
주식매수선택권부여에관한신고
Korean 21.5 KB
2025-07-25 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 368.6 KB
2025-07-17 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 77.7 KB
2025-07-10 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의
Korean 16.8 KB
2025-06-25 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 10.7 KB
2025-06-25 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.2 KB
2025-06-04 00:00
Major Shareholding Notification
[기재정정]주식등의대량보유상황보고서(일반)
Korean 372.2 KB
2025-06-04 00:00
Major Shareholding Notification
[기재정정]주식등의대량보유상황보고서(일반)
Korean 360.6 KB
2025-05-26 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.7 KB

Automate Your Workflow. Get a real-time feed of all Orum Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Orum Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Orum Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden
2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom
4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America
SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America
AARD
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America
ABBV
ABEONA THERAPEUTICS INC. Logo
Developing AAV-based cell and gene therapies for serious and rare diseases.
United States of America
ABEO
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden
ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom
ABDX

Talk to a Data Expert

Have a question? We'll get back to you promptly.